Investors in the Ysios BioFund I will see the first returns on their investment, many before the 5 to 7 years that constitute the average in the venture capital sector.
Invest in Spain offers aid valued at 1,600,000 euros for companies that start up operations in any region of the country or those already established that begin R&D&i activities.
The great breakthrough of this new device, which will go on the market in 2012, is that it reduces patient pain and risk of infection, as well as obtaining data faster and more precisely.
Neurofarmagen TDAH® is a genetic analysis that allows doctors to see how a patient will react to the most common attention deficit and hyperactivity disorder drugs and helps evaluate future risks.
